Remodeling of MHC-related Immune Microenvironment in MIBC After Neoadjuvant Therapy

Inclusion Criteria: * Male or female, aged ≥18 years. * Expected survival ≥12 weeks. * Diagnosed by histopathology as muscle-invasive bladder urothelial carcinoma (MIBC) without upper urothelial carcinoma. * Clinical stage (cT2-T4a, N0-1, M0) and no distant metastasis as evaluated by imaging. * The subjects were assessed by urologists as tolerable and planned radical cystectomy. * ECOG Physical Condition 0-2. Exclusion Criteria: * Patients with previous malignant tumors were not eligible to participate in the study unless they had achieved complete remission for at least 5 years prior to enrollment and did not require additional treatment or did not require additional treatment during the study. * Combined with serious internal medical diseases including but not limited to: uncontrolled diabetes, active peptic ulcer, active bleeding, etc. * Patients with insufficient communication, understanding and cooperation, or poor compliance, cannot be guaranteed to complete follow-up as required.